New Report Shows Parkinson’s Costs Surpass $82 Billion in US in 2024
The economic burden Parkinsons disease imposes in 2024 exceeds $82 billion in the US. This figure underscores the urgent need for cost-effective therapeutic interventions. Cannabis medicine shows emerging evidence for managing motor and non-motor…
CurePSP Leads Bipartisan Briefing to Boost PSP, CBD, and MSA Research
Rare neurodegenerative diseases research is critical for conditions like PSP, CBD, and MSA, which currently lack effective treatments. CurePSP convened a bipartisan congressional briefing to increase awareness and funding. This advocacy aims to…
New Funding to Support SER-252 Trial in Advanced Parkinson’s
The synthetic cannabinoid Parkinsons trial SER-252 targets levodopa-induced dyskinesia in advanced Parkinson's disease. This novel therapeutic approach could improve management of motor symptoms. Ongoing research aims to validate its clinical efficacy…
Understanding Corticobasal Degeneration at Pacific Neuroscience Institute
Corticobasal degeneration neuroprotection is a critical area of research due to the disease's devastating progression. Cannabis shows promise in symptom management and neuroprotective effects for this rare disorder. Understanding these potentials can aid…